MaxWell Biosystems passes the final stage of Venture Kick and wins CHF 100’000. After presenting at the final stage, MaxWell Biosystems convinced the Venture Kick jury and secured CHF 100’000, in addition to CHF 30’000 already granted in previous stages. Venture Kick supports the first steps of the realization of a business idea and awards selected start-ups with up to CHF 130’000 seed money. The final stage serves as the culmination of the year-long journey of MaxWell Biosystems with Venture Kick. The journey started last July…
MaxWell Biosystems gets more media coverage. ETH Zurich News features the spin-off company MaxWell Biosystems. The article highlights the company’s core technology developed in Hierlemann Lab (D-BSSE) and the motivation to commercialize thanks to the demand of induced pluripotent stem cell boom. Link to English version >> Link to German version >>
MaxWell Biosystems participated at the startup presentation event “Startup Champions Seed Night” on the 26th of April in the Rolex Learning Center Forum in EPFL. The event was co-organized by EPFL Alumni, the Innogrants and venturelab. A nice audience of 400 people attended the event.
MaxWell Biosystems was successfully preselected as one of the 10 nominees for the W. A. De Vigier Stiftung award. The Award Ceremony will take place in Solothurn on the 18th of May 2017. The William A. De Vigier foundation provides assistance to young Switzerland entrepreneurs. Since its 28th anniversary, the foundation has distributed over 10 million francs of start-up capital.
MaxWell Biosystems exhibited MaxOne at the BNA 2017 Festival of Neuroscience on April 10-13, 2017 at the ICC, Birmingham. BNA 2017 is one of the largest neuroscience conferences in Europe this year organized by the British Neuroscience Association. Our MaxOne high-resolution technology attracted a lot of interest. And this is not just because of our magic levitation device, but much more because it allows to monitor neuronal activity at various scales, from full networks, to single-cell activity and even subcellular features. We…
After a competitive process, Maxwell Biosystem has been selected as one of the ten members of the Venture Leaders Life Sciences 2017 team. Ten new Swiss innovative start-ups will take part in a startup development program in Boston, Massachusetts on June 11-17, 2017. This “business boosting” week, co-organized by venturelab and swissnex Boston, will enable the selected swiss startups to take the first steps towards their global expansion.
MaxWell Biosystems presented MaxOne at the 96th annual meeting of the Deutsche Physiologische Gesellschaft in Greifswald, Germany on March 16-18, 2017. The German Physiology Society meeting was held at one of the oldest universities in Germany, University of Greifswald (founded 1456). The meeting was participated by researchers working on diverse areas of physiology, including cardiac cell physiology and cellular neuroscience.
MaxWell Biosystems exhibited MaxOne with its newly developed data acquisition unit at the SelectBio Advances in Drug Discovery Conference in Hinxton, Cambridge, UK. It was an exciting meeting, attended by many researchers who are currently screening for efficacy and toxicity using iPS cell lines or developing enabling techniques and technologies for this. Progress in stem cell biology is revolutionizing drug discovery research now; the ability to grow and differentiate stem cell lines is providing a far more relevant model for…
The paper by K. Yonehara*, M. Fiscella*, A. Drinnenberg*, et al. entitled “Congenital Nystagmus Gene FRMD7 is necessary for establishing a neuronal circuit asymmetry for direction selectivity” was chosen for the “Best of Neuron” selection 2015-2016. “Best of Neuron“ includes ground-breaking neuroscience research published in Neuron and is a collection of editors’ and readers’ favorites. MaxWell Biosystems HD-MEA core technology was used in this study, to characterize the disease phenotype discovered in the FRMD7 mutant retina. Mutation in the FRMD7 gene is linked to the…
MaxWell Biosystems successfully cleared Venture Kick Stage 2 and received CHF 20,000. See Venture Kick news here >> Venture Kick finances start-ups at the early stage with a grant of up to CHF 130,000 and provides professional support of business experts.
MaxWell Biosystems presented MaxOne at MipTec 2016 in Basel. As one of the events during Basel Life Science Week, over 100 life science companies worldwide gathered at the MipTec International Life Science Exhibition. The MaxWell Biosystems booth was located in the Innovation Village next to other start-up companies. Dr. Michele Fiscella, VP Scientific Affairs, gave daily product presentations on the features and applications of the MaxOne technology.
MaxWell Biosystems exhibited MaxOne and its applications for Cardiac Safety Pharmacology at the 2016 Safety Pharmacology Society (SPS) / Japanese Safety Pharmacology Society (JSPS) / Canadian Society of Pharmacology and Therapeutics (CSPT) Joint Meeting in Vancouver, BC, Canada. The meeting, held from the 18th to 21st of September 2016, had over 568 attendees from around the world, with 253 abstracts presented and 51 exhibiting companies.
MaxWell Biosystems received the ETH spin-off label and joins the strong list of ETH spin-off companies. MaxWell Biosystems continues to be in close collaboration with Prof. Dr. Andreas Hierlemann and the Bio Engineering Laboratory, Department of Biosystems Science and Engineering in Basel.
We are delighted to announce the official registration of MaxWell Biosystems AG in Canton Basel-City, Switzerland. MaxWell Biosystems is now part of Basel’s booming life science and tech start-up community with its close vicinity to multinational biotech and pharmaceutical companies.
MaxWell Biosystems gets through the first round of Venture Kick and receives CHF 10,000 grant. The team will attend the kickers camp on September and then proceed to Stage 2 of the competition, with an opportunity to win an additional CHF 20,000. See the VentureKick news here.